



PRESS RELEASE

"RNAVENIR" Project Funding granted by French Government to support the Development of Tebubio RNA Platform

Le Perray-en-Yvelines, May 2024

Following the "CRO" (Contract Research Organization) call for projects launched in December 2022 by the French Government, Tebubio has received funding from France 2030 for its RNAVENIR project, to further improve the performance and development of its RNA activities.

RNA at the heart of the RNAVENIR project

The RNAVENIR project will enable Tebubio to increase production yields, develop new encapsulation strategies and extend its range of services to accelerate research for its private and public sector customers. This project, certified by Medicen Paris Région, is in line with the French government's priority objectives through the "biotherapies and bioproduction of innovative therapies" acceleration strategy present in the France 2030 plan.

Acceleration of Tebubio's research projects

Tebubio's fast, high-purity production of customized RNAs for therapeutic applications is key to validate new proof-of-concepts for RNA-based biotherapies.

With around 100 employees in several European offices, the government funding will enable Tebubio to continue developing its CRS – Contract Research Services – to support organizations based in France and abroad, in order to accelerate their Life Sciences research projects.

"This recognition of our capabilities by the Prime Minister's office encourages our teams to continue to support our customers by making their everyday research work easier." said Donald van Dijk, CEO of Tebubio. This is an opportunity for Tebubio to continue its mission: contributing to advance Science for a brighter future."

About France 2030

Presented on October 12, 2021 by Emmanuel Macron, President of the Republic of France, France 2030:

✓ Translates a dual ambition: to sustainably transform key sectors of our economy (energy, automotive, healthcare, aeronautics and space) through technological and industrial innovation, and to position France not just as a player, but as a leader in the world of tomorrow. From fundamental research and the emergence of an idea, to the production of a new product or service, France 2030 supports the entire life cycle of innovation, right through to industrialization.

- ✓ The scale of the program is unprecedented: €54 billion will be invested so that our companies, universities and research organizations can successfully make the transition to these strategic sectors. The aim is to enable them to respond competitively to the ecological and attractiveness challenges of the coming world, and to create the future champions of our sectors of excellence, thereby strengthening French sovereignty and independence in key sectors. To this end, 50% of spending will be devoted to decarbonizing the economy, and 50% will be earmarked for emerging players, bringing innovation with no adverse impact on the environment (in line with the *Do No Significant Harm* principle).
- ✓ Will be collectively implemented: the plan is designed and deployed in consultation with economic, academic, local and European players, who have helped to determine its strategic orientations and flagship actions. Project leaders are invited to submit their applications via open, but demanding and selective procedures, in order to benefit from government support.
- ✓ Led by the Secrétariat Général pour l'Investissement on behalf of the Prime Minister, and implemented by the "Agence de la Transition Ecologique" (ADEME), the "Agence Nationale de la Recherche" (ANR), "Bpifrance" and the "Caisse des Dépôts et Consignations" (CDC).

Further information: france2030.gouv.fr

About Tebubio

We facilitate Life Sciences Research every day, contributing to advance Science for a brighter future. Through our local offices located across Europe, we support Life Sciences and Biotechnology Researchers with a unique, holistic range of solutions to advance their projects faster.

With Tebubio, concentrate your efforts and accelerate what's most important to you: Your Research.

Further information: <u>tebubio.com</u>

Press contact

Cyrielle Delafoy, Corporate Communications Specialist Tel: +33 (1) 30 46 39 88 Email: <u>communication@tebubio.com</u>